Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome.
Sacchi A, Grassi G, Bordoni V, Lorenzini P, Cimini E, Casetti R, Tartaglia E, Marchioni L, Petrosillo N, Palmieri F, D'Offizi G, Notari S, Tempestilli M, Capobianchi MR, Nicastri E, Maeurer M, Zumla A, Locatelli F, Antinori A, Ippolito G, Agrati C. Sacchi A, et al. Among authors: lorenzini p. Cell Death Dis. 2020 Oct 27;11(10):921. doi: 10.1038/s41419-020-03125-1. Cell Death Dis. 2020. PMID: 33110074 Free PMC article.
Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.
Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, Gori C, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test (GRT) at National Institute for Infectious Diseases Lazzaro Spallanzani. Zaccarelli M, et al. Among authors: lorenzini p. AIDS. 2005 Jul 1;19(10):1081-9. doi: 10.1097/01.aids.0000174455.01369.ad. AIDS. 2005. PMID: 15958840
Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort.
Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A, Vlassi C, Larussa D, Zaccarelli M, Noto P, Visco-Comandini U, Giulianelli M, Ippolito G, Antinori A, Narciso P. Tozzi V, et al. Among authors: lorenzini p. J Neurovirol. 2005 Jul;11(3):265-73. doi: 10.1080/13550280590952790. J Neurovirol. 2005. PMID: 16036806
Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART.
Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, Piselli P, Lorenzini P, Visco-Comandini U, Vlassi C, Quartuccio ME, Giulianelli M, Noto P, Galgani S, Ippolito G, Antinori A, Narciso P. Tozzi V, et al. Among authors: lorenzini p. AIDS Res Hum Retroviruses. 2005 Aug;21(8):706-13. doi: 10.1089/aid.2005.21.706. AIDS Res Hum Retroviruses. 2005. PMID: 16131310
Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy.
Giancola ML, Lorenzini P, Balestra P, Larussa D, Baldini F, Corpolongo A, Narciso P, Bellagamba R, Tozzi V, Antinori A. Giancola ML, et al. Among authors: lorenzini p. J Acquir Immune Defic Syndr. 2006 Mar;41(3):332-7. doi: 10.1097/01.qai.0000197077.64021.07. J Acquir Immune Defic Syndr. 2006. PMID: 16540934
Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test. Tozzi V, et al. Among authors: lorenzini p. Antivir Ther. 2006;11(5):553-60. Antivir Ther. 2006. PMID: 16964822
226 results